Sign up to save your podcasts
Or
Share S2E5: Why Pharma Needs Immutable Data | Around the Block With Special Guest Host Bert Fernandez
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S2E5: Why Pharma Needs Immutable Data | Around the Block With Special Guest Host Bert Fernandez
Around the Block Podcast by Circular Protocol featuring the Bright Path Laboratories Team, with Special Guest Host Bert Fernandez (Host of the HealthTech2Care Podcast).
In this episode, the Bright Path Laboratories Team shares why the U.S. pharmaceutical supply chain remains heavily dependent on offshore manufacturing for essential medicines and generic drugs, and why data integrity matters when patients' lives depend on the medicines they take.
We unpack how Bright Path's patented continuous-flow Spinning-Tube-in-Tube (STT) Reactor™ enables safer, more sustainable, and more cost-effective production of small-molecule drugs in the U.S., and why continuous manufacturing changes the economics of pharma.
The conversation also explores how machine learning and blockchain are being used together to create immutable manufacturing data, providing proof of trust for regulators, partners, and ultimately patients.
Highlights:
- Why immutable data is critical for pharmaceutical manufacturing
- How offshore API dependence impacts quality, cost, and resilience
- What continuous-flow chemistry enables that batch manufacturing cannot
- The role of ML in monitoring drug production in real time
- Why blockchain matters for trust, traceability, and compliance
Timestamps:
00:00 Intro
01:06 What does sustainable small-molecule pharma manufacturing mean at Bright Path, and what makes your approach different?
04:03 Why focus on small-molecule generics and onshoring drug manufacturing in the US?
06:55 What personally drew you to this mission and to working on cleaner, more responsible chemistry?
13:14 How are you thinking about decentralized systems and proof of trust in pharma manufacturing?
18:37 Why did you choose Circular's Layer-1 blockchain over other blockchain options?
22:52 Where is this all headed, and what does the future of drug manufacturing look like with these technologies?
Guests: Tony Quinones (CEO):
🔗 LinkedIn: https://www.linkedin.com/in/tquinones
🌐 Website: https://brightpathlabs.com
Michael A. Gonzalez, PhD (Chief Scientific Officer):
🔗 LinkedIn: https://www.linkedin.com/in/michael-a-gonzalez-ph-d-5398276
Ajaz Hussain, PhD (Strategic Advisor)
🔗 LinkedIn: https://www.linkedin.com/in/ajazshussain
Special Guest Host:
Bert Fernandez (Founder, HealthTech2Care)
🔗 LinkedIn: https://www.linkedin.com/in/bert-fernandez
🌐 Website: https://www.healthtech2care.com
📺 YouTube: https://www.youtube.com/@HealthTech2Care
Learn more about Bright Path Laboratories: https://brightpathlabs.com
and Circular Protocol: https://circularlabs.io
🔔 Subscribe to the HealthTech2Care YouTube channel for more in-depth conversations with healthcare and life sciences innovators: https://www.youtube.com/@HealthTech2Care
#PharmaManufacturing #ImmutableData #SmallMoleculeDrugs #LifeSciences #Blockchain #SupplyChain #HealthcareInnovation
View all episodes
By Bert FernandezAround the Block Podcast by Circular Protocol featuring the Bright Path Laboratories Team, with Special Guest Host Bert Fernandez (Host of the HealthTech2Care Podcast).
In this episode, the Bright Path Laboratories Team shares why the U.S. pharmaceutical supply chain remains heavily dependent on offshore manufacturing for essential medicines and generic drugs, and why data integrity matters when patients' lives depend on the medicines they take.
We unpack how Bright Path's patented continuous-flow Spinning-Tube-in-Tube (STT) Reactor™ enables safer, more sustainable, and more cost-effective production of small-molecule drugs in the U.S., and why continuous manufacturing changes the economics of pharma.
The conversation also explores how machine learning and blockchain are being used together to create immutable manufacturing data, providing proof of trust for regulators, partners, and ultimately patients.
Highlights:
- Why immutable data is critical for pharmaceutical manufacturing
- How offshore API dependence impacts quality, cost, and resilience
- What continuous-flow chemistry enables that batch manufacturing cannot
- The role of ML in monitoring drug production in real time
- Why blockchain matters for trust, traceability, and compliance
Timestamps:
00:00 Intro
01:06 What does sustainable small-molecule pharma manufacturing mean at Bright Path, and what makes your approach different?
04:03 Why focus on small-molecule generics and onshoring drug manufacturing in the US?
06:55 What personally drew you to this mission and to working on cleaner, more responsible chemistry?
13:14 How are you thinking about decentralized systems and proof of trust in pharma manufacturing?
18:37 Why did you choose Circular's Layer-1 blockchain over other blockchain options?
22:52 Where is this all headed, and what does the future of drug manufacturing look like with these technologies?
Guests: Tony Quinones (CEO):
🔗 LinkedIn: https://www.linkedin.com/in/tquinones
🌐 Website: https://brightpathlabs.com
Michael A. Gonzalez, PhD (Chief Scientific Officer):
🔗 LinkedIn: https://www.linkedin.com/in/michael-a-gonzalez-ph-d-5398276
Ajaz Hussain, PhD (Strategic Advisor)
🔗 LinkedIn: https://www.linkedin.com/in/ajazshussain
Special Guest Host:
Bert Fernandez (Founder, HealthTech2Care)
🔗 LinkedIn: https://www.linkedin.com/in/bert-fernandez
🌐 Website: https://www.healthtech2care.com
📺 YouTube: https://www.youtube.com/@HealthTech2Care
Learn more about Bright Path Laboratories: https://brightpathlabs.com
and Circular Protocol: https://circularlabs.io
🔔 Subscribe to the HealthTech2Care YouTube channel for more in-depth conversations with healthcare and life sciences innovators: https://www.youtube.com/@HealthTech2Care
#PharmaManufacturing #ImmutableData #SmallMoleculeDrugs #LifeSciences #Blockchain #SupplyChain #HealthcareInnovation